Remunerated MedsChecks are set to double and payments for DAAs streamlined under an $825 million provision for pharmacy over the next three years
The provision of $825 million is aimed at supporting and improving Australians’ access to medicines under the “Improving Access to Medicines – support for community pharmacies” measure.
It comprises the $600 million in the 6CPA for pharmacy programs, plus the $225 million to go to community pharmacists and pharmaceutical wholesalers as a result of lower than forecast script volumes.
Changes are set to begin from 1 July 2017.
Last week Guild national president George Tambassis said the Guild was engaged in “very detailed and urgent discussions with the Department of Health to finalise these allocations by 1 July”.
Dose Administration Aids
The current Pharmacy Practice Incentive payment for DAAs will wind up on 30 June 2017, though claims for DAAs provided in June may be submitted between 1 July and 14 July 2017.
From 1 July, community pharmacies participating in the DAA program will receive $6 per patient per week as a contribution to the cost of providing the service to eligible patients.
Pharmacies may apply an additional consumer charge for the DAA service at their own discretion.
To support the collection of information and monitor the program’s delivery of health outcomes for patients, they will be required to collect data for five patients that receive services.
MedsChecks and Diabetes MedsChecks
From 1 July 2017, the number of MedsCheck and Diabetes MedsChecks that can be conducted and claimed by community pharmacies are set to double, from 10 per calendar month to a total of 20 per calendar month.
Again, to support the collection of information and monitor the program’s delivery of health outcomes for patients, community pharmacies will be required to collect data for the patients funded under this service.
The current Pharmacy Practice Incentive payment of $1,300 a year for Staged Supply will come to an end on 30 June 2017.
From 1 July 2017, community pharmacies participating in the Staged Supply program will receive a new weekly fee-for-service per patient for up to four eligible patients per pharmacy.
Community pharmacies will be required to collect data for the patients funded under the service.
The HMR program will continue unchanged from 1 July 2017, but a review of the current MBS item 900 eligibility criteria is to be undertaken.
Potential changes to patient eligibility criteria, the inclusion of two new in-pharmacy follow-up services, and criteria to increase access to the service for Aboriginal and Torres Strait Islander patients are anticipated to commence in early 2018.
More information is available here.